Press Releases
9 February, 2012
Altheos Announces Initiation of Phase 2a Clinical Trial for its
Lead
Glaucoma Drug Candidate, ATS907
30 September, 2010
Altheos Names Barbara Wirostko, M.D., Chief Medical Officer
5 April, 2010
Altheos Completes $20 Million Series
A Financing to Develop Next-Generation Glaucoma Treatment
| 